Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation

Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic... Ann Hematol (2017) 96:1569–1572 DOI 10.1007/s00277-017-3033-7 LETTER TO THE EDITOR Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation 1 1 1 Thomas S. Y. Chan & Joycelyn P. Y. Sim & Yok-Lam Kwong Received: 22 May 2017 /Accepted: 23 May 2017 /Published online: 1 June 2017 Springer-Verlag Berlin Heidelberg 2017 Dear Editor, Patient 1 was a 31-year-old woman presenting in 2013 with Relapse of acute leukaemia after allogeneic haematopoietic B cell ALL. Induction chemotherapy with hyper-CVAD (cy- stem cell transplantation (HSCT) has a dismal prognosis, de- clophosphamide, vincristine, doxorubicin, steroid, cytarabine, spite the use of chemotherapy, donor lymphocyte infusion methotrexate) resulted in first complete remission (CR1). She underwent a matched unrelated donor (MUD)-HSCT. Relapse (DLI) or second HSCT [1]. For relapses within 1 year post- HSCT, current strategies lead to survival in fewer than 10% of occurred 10 months later, and CR2 was achieved with MOAD cases [1, 2]. (methotrexate, vincristine, L-asparaginase, dexamethasone). Immunotherapy including the use of monoclonal antibod- She then received a second MUD-HSCT from a different do- ies inotuzumab ozogamicin (anti-CD22) and blinatumomab nor. Five months later, multiple subcutaneous nodules, renal (anti-CD19) [3], and chimeric antigen receptor T cells [4], http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation

Loading next page...
 
/lp/springer_journal/low-dose-nivolumab-induced-responses-in-acute-lymphoblastic-leukaemia-zH00FYQJwQ
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
D.O.I.
10.1007/s00277-017-3033-7
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial